The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 4

Conditions: Diabetes Mellitus Non-insulin-dependent

Treatments: Drug: sitagliptin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00832624

2009_526

0431-118

Details and patient eligibility

About

to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.

Enrollment: 10 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients Who Are 18 Years Of Age With Type 2 Diabetes Mellitus Who Are Either:

  • Not On Antihyperglycemic (AHa) Medication (Off For At Least 2 Months)
  • Or On A Single AHa

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

1

Experimental group

Description:

sitagliptin

Treatment:

Drug: sitagliptin